According to a recent Associated Press report, nearly all people hospitalized with Covid19 have not been vaccinated – as of May, 99.9% to be precise.
However, according to data from the Caesars Family Foundation’s COVID19 vaccine monitor, 13% of American adults said they will “absolutely not get” the COVID19 vaccine by the end of May. Another 12% want to “wait until it is available for a period of time and see how effective it affects others.”
Vaccination for the majority of the population is to help prevent the evolution of mutations (for example, currently in the United States and other countries) The rapid spread of delta mutations) is the best way to cause more overloads.
However, Noubar Afeyan, Moderna’s co-founder, understands the doubts about obtaining a new vaccine.
“Vaccines have been around for such a short period of time that people unconsciously believe they cannot be safe,” Afeyan said in a speech at the Massachusetts Institute of Technology in May.
“In fact, many, many people support this view of television experts in this area, if it is completed in less than five years, it must be unsafe, all of which is false …
” However, the people are still confused.
What people may not understand is that mRNA technology and other mRNA vaccines have been studied extensively for many years. More than a decade of experience and innovation in mRNA technology has enabled Moderna to produce them so quickly when a pandemic strikes. Covid mRNA. It may also change the future of medicine.
Here’s what you need to know about how the Modern Covid19 mRNA vaccine was developed.
Schedule: vaccine less than one year
Moderna’s mRNA vaccine is prepared very quickly, as is Pfizer’s. On January 11,
Chinese scientists posted the genetic sequence of the new coronavirus on the Internet. Over the next two days, NIH and Moderna used it to design vaccines.
Afeyan recalls receiving a key call about the development of the Covid19 vaccine. “On January 21, my daughter’s birthday… I received a call from the CEO of Moderna from Davos (during the World Economic Forum),” he said. Various public health organizations contacted Bansell at the meeting and “urged” him to research vaccines.
“We really decided overnight…try to do this,” Afeyan said at MIT.
Moderna delivered the first dose of the Covid19 vaccine to NIH on February 2 for testing. Afeyan stated that on March 24, 2020, “Moderna’s first injection entered the arm of a volunteer in Seattle on March 16, 2020.”
After testing the Moderna vaccine on 30,000 volunteers, on December 18, 2020, the FDA approved it for emergency public use. Three days later, the first batch of Moderna vaccine was used by frontline medical staff, according to Afeyan.
After more than ten years of research, innovating mRNA as a “biological platform” One of the reasons why
Moderna’s Covid mRNA vaccine has developed so rapidly is because scientists have been studying mRNA for many years.
“Messenger RNA technology has been developing from a basic science point of view for more than 15 years,” Kizzmekia Corbet, scientific leader of the NIH immunopathogenesis and coronavirus vaccine team, told NIH Records that this helped make vaccines possible.
Afeyan told CNBC Make It (via a publicist), “Since its establishment in 2010, Moderna has been researching mRNA technology for countless therapeutic areas,” including cancer treatment, and has been making mRNA-based antiviral vaccines. since 2015 Clinical development.
What Moderna has done for many years is develop mRNA on what scientists call a biological platform, so that vaccines can develop faster. The biological platform is a system that can be easily expanded and customized for many different diseases.
Traditionally, the development of any vaccine is basically a custom job.
“The advantage of the biological platform is the ability to rapidly redeploy the platform after it has been established and improved; in the case of Moderna’s mRNA platform, new vaccines based on new sequences of virus, “Afeyan told CNBC Make Es (for public relations).
All of this makes the mRNA vaccine almost programmable. Corbet and Bancel describe this process as “plug and play.”
“mRNA is always made up of four identical letters,” Bansell said in Anderson Horowitz’s December podcast, “The World Eater by Biology”. (MRNA is genetic material, similar to DNA, so its “code” is represented by letters). Bancel said that they are “the four letters of life, just like the 0 and 1 in software.” “It’s like software or Lego.”
“The only difference between mRNA vaccines is the order of letters; zero and one in life,” Bansell said. “The manufacturing process is the same, the equipment is the same, and the operators are the same. it’s the same. This is why we can go so fast. ”
Faster vaccine development in the future. The
bio-platform will produce changes far beyond the Covid pandemic.
Judy Savitskaya and Jorge Conde, the biotech investors of Silicon Valley’s major investment company Andreessen Horowitz, compare how bio-platforms transform the biotech industry into What the new assembly line does for the automotive industry: “It’s transformed from the single workshop of the car’s early days, where raw materials such as steel and rubber were written by them in a blog post in January
. The trickle to assembly line production, and standard components that can be iterated for new models (Andreessen Horowitz is not an investor in Moderna), Pfizer or BioNTech, according to a company spokesperson. ) An example of how the
Covid19 vaccine uses mRNA. According to the company’s quarterly investment report released in May,
Moderna has 24 mRNA vaccines and therapies under investigation, and 14 have already started clinical trials. Moderna’s mRNA therapy product portfolio includes Zika vaccines, HIV vaccines and cancer vaccines.
Enable the same dynamic